What’s New

Casting a wider net than ever before, JMJ is expanding our activities to include a variety of debt and equity structures designed to fuel the growth of an ever increasing number of issuers. To communicate our wide range of investment options, we’ve redesigned our website… Read more

In today’s world of investment committees, underwriting criteria, and regulatory oversight, finding financing that meets your company’s or client’s specific needs can be a daunting task. But it also can be a critical component of growth and success. That’s where JMJ Financial is unique. We’re… Read more

Your ideal investment partner should mirror the traits you’d seek in any relationship. That’s why many investment banking pundits recommend seeking out specific qualities in an investor rather than simply the best terms for a specific transaction. The commitment, stability, connections, persistence and transparency of… Read more

On August 2, Advaxis, Inc. (NASDAQ: ADXS) and Amgen announced an agreement for the development and commercialization of Advaxis’ novel cancer immunotherapy treatment, providing Advaxis with milestone payments of up to $475 million in addition to royalties. Advaxis is developing a number of other immunotherapies… Read more

JMJ Financial is well known for our innovative Quickloans, the fastest, simplest way for growth companies to obtain unsecured capital, often within a few days, and without revenue or share price requirements. Over 250 companies have taken advantage of our Quickloan program to power their… Read more